Amprion
Latest round
- Series B
Last raised
- Sep 2024
Total raised
- $5.8M
Investors
- 2
About Amprion
Based in California, US, and founded in 2007, Amprion, Inc. operates as a biotechnology company that develops precision medicine for neurodegenerative diseases. The company was founded by its CEO, Russ Lebovitz, and CSO, Claudio Soto. Amprion develops tests to diagnose brain disorders, including Parkinson's and Lewy Body Dementia. The company's product line includes the SYNTap Biomarker Test, which detects misfolded proteins (prions) in the cerebrospinal fluid (CSF) associated with neurodegenerative diseases like Alzheimer's, Parkinson's, and Lewy body dementia. By detecting these misfolded proteins, the SYNTap® test helps doctors diagnose these diseases earlier. The firm uses biomarker testing to develop precision medicine for these diseases.
Who invested in Amprion
2 investors across 1 round
See all investors in Amprion
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Sep 10, 2024
Amount
$5.8M
Investors
Questions about Amprion
Who invested in Amprion?
Amprion has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Amprion raised?
Amprion has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Amprion last raise money?
Amprion's most recent round on record is a Series B, in Sep 2024.
What does Amprion do?
Based in California, US, and founded in 2007, Amprion, Inc.
Where is Amprion headquartered?
Amprion is headquartered in San Diego, US.
Which VCs invest in companies like Amprion?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Amprion's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Amprion? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.